Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 7, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00380-22
Keywords
APX001; APX001A; Gwt1; antifungal; aspergillosis; mucormycosis; fusariosis infection model; IPA; 1-aminobenzotriazole; manogepix; fosmanogepix; fusariosis; infection model
Categories
Funding
- Public Health Service [R01 AI063503]
- Amplyx Pharmaceuticals
Ask authors/readers for more resources
This study evaluated the benefit of combination therapy with FMGX and L-AMB in severe invasive mold infections. The results showed that combination therapy was more effective than monotherapy in improving survival rates and reducing fungal burden in mouse models.
Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis (IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in-class antifungal in clinical development with demonstrated broadspectrum activity in animal models of infections. We sought to evaluate the benefit of combination therapy of FMGX plus liposomal amphotericin B (L-AMB) in severe delayed-treatment models of murine IPA, IM, and IF. While FMGX was equally as effective as L-AMB in prolonging the survival of mice infected with IPA, IM, or IF, combination therapy was superior to monotherapy in all three models. These findings were validated by greater reductions in the tissue fungal burdens (determined by quantitative PCR) of target organs in all three models versus the burdens in infected vehicle-treated (placebo) or monotherapy-treated mice. In general, histopathological examination of target organs corroborated the findings for fungal tissue burdens among all treatment arms. Our results show that treatment with the combination of FMGX plus L-AMB demonstrated high survival rates and fungal burden reductions in severe animal models of invasive mold infections, at drug exposures in mice similar to those achieved clinically. These encouraging results warrant further investigation of the FMGX-plus-L-AMB combination treatment for severely ill patients with IPA, IM, and IF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available